

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 223 13-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/568,704	02/16/2006	Karlheinz Bortlik	· 112701706	4852
	7590 02/12/2008 & LLOYD LLP	EXAMINER		
P.O. Box 1135		MI, QIUWEN		
CHICAGO, IL	00090		ART UNIT PAPER NUMBER	
			1655	
	•			
			NOTIFICATION DATE	DELIVERY MODE
			02/12/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATENTS@BELLBOYD.COM

		Application No.	Applicant(s)			
		10/568,704	BORTLIK ET AL.			
Office Action S	Summary	Examiner	Art Unit			
		Qiuwen Mi	1655			
	of this communication app	ears on the cover sheet with the c	orrespondence address			
Period for Reply		/ IC OFT TO EVOIDE AMONTH	COOR THIRTY (20) DAVE			
WHICHEVER IS LONGER, - Extensions of time may be available after SIX (6) MONTHS from the maili - If NO period for reply is specified abo - Failure to reply within the set or exten	FROM THE MAILING DA under the provisions of 37 CFR 1.11 ng date of this communication. ove, the maximum statutory period vended period for reply will, by statute than three months after the mailing	Y IS SET TO EXPIRE 3 MONTH(ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE and the description of the communication of the	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1) Responsive to commu	unication(s) filed on 29 N	<u>ovember 2007</u> .	•			
2a)⊠ This action is FINAL .	This action is FINAL . 2b) This action is non-final.					
3) Since this application	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance	with the practice under E	x parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.			
Disposition of Claims						
4)⊠ Claim(s) <u>1-12,14 and</u>	15 is/are pending in the a	application.				
4a) Of the above claim(s) <u>6-8,12,14 and 15</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-5 and 9-11</u>	is/are rejected.					
7) Claim(s) is/are	·					
8) Claim(s) are su	ubject to restriction and/o	r election requirement.				
Application Papers	·					
9) The specification is ob	jected to by the Examine	r. ·				
10) The drawing(s) filed onis/ are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	•	ion is required if the drawing(s) is ob carniner. Note the attached Office				
Priority under 35 U.S.C. § 119		•				
12)⊠ Acknowledgment is m	ade of a claim for foreign	priority under 35 U.S.C. § 119(a)-(d) or (f).			
a) ☐ All b) ☐ Some * c						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
	•					
Attachment(s)						
 Notice of References Cited (PTC Notice of Draftsperson's Patent I 		4) Interview Summary Paper No(s)/Mail D				
Notice of Draftsperson's Patent I Information Disclosure Statemen Paper No(s)/Mail Date	-	5) Notice of Informal F 6) Other:				

10/568,704 Art Unit: 1655

DETAILED ACTION

Applicant's amendment in the reply filed on 11/29/07 is acknowledged. Any rejection that is not reiterated is hereby withdrawn.

Claims Pending

Claim 13 is cancelled. Claims 1-12, 14, and 15 are pending. Claims 6-8, 12, 14, and 15 are withdrawn as they are directed toward a non-elected invention group. Claims 1-5, and 9-11 are examined on the merits.

Claim Rejections –35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-5, and 9-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bortlik et al (US 2002/0107292).

This rejection is maintained for reasons of record set forth in the Office Action mailed out on 8/29/2007. Applicants' arguments filed have been fully considered but they are not deemed to be persuasive.

Application/Control Number:

10/568,704

Art Unit: 1655

Applicant argues that *Bortlik* fails to disclose or suggest a natural lycopene concentrate as required, in part, by the present claims. Rather, *Bortlik* teaches a lycopene concentrate having modified native characteristics by virtue of being mixed with a solvent. Specifically, *Bortlik* teaches two processes for preparing a lycopene composition, both of which require mixing the lipophilic bioactive compound with a solvent, the solvent preferably being acetone, isoproponol or ethanol (page 2, 4th paragraph). By contrast to *Bortlik*, the present claims require a "natural" lycopene concentrate, meaning that the product has only been subject to technological treatments that do not modify its native characteristics (page 2, 5th paragraph).

Applicant's argument is not found persuasive. In one of the embodiment, *Bortlik* does teach "the composition may be formed by dissolving the whey protein to form a first solution, dissolving the lipophilic bioactive compound in a solvent to form a second solution, combining the two solutions, and evaporating the solvent to form the composition as a dispersion" [0009]. Although solvent was used to enhance the solubility of lipophilic bioactive compound, it was being evaporated after the composition was formed. Therefore, the solvent does not alter native characteristics lycopene. In addition, plant extracts are being called natural products, although varieties of solvents were being used during the extraction and isolation process. Furthermore, in the specification of the current application (page 9, 4th paragraph), the tomato paste was alkalinized with a base of the NaOH type, and NaOH is definitely not "natural", and it certainly alters the native characteristics of lycopene more than a solvent which was eventually being evaporated.

10/568,704 Art Unit: 1655

Applicant's arguments have been fully considered but they are not persuasive, and therefore the rejections in the record are maintained.

Conclusion

No claim is allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Qiuwen Mi whose telephone number is 571-272-5984. The examiner can normally be reached on 8 to 5.

10/568,704

Art Unit: 1655

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on 571-272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Qiuwen Mi

/Patricia Leith/

Primary Examiner, Art Unit 1655

2/6/08